RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
   Small Cell Carcinoma
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Archives of Internal Medicine Lung Channel

subscribe to Lung newsletter
Latest Research : Cancer : Lung

   EMAIL   |   PRINT
Tumor diameter - an important prognostic indicator for curability

Feb 15, 2006 - 2:55:00 PM , Reviewed by: Rashmi Yadav
"Most lung cancers without evidence of lymph node metastases are curable, with the curability rate being higher at smaller sizes."

[RxPG] Smaller tumors in the lungs appear to be less likely to have spread than larger tumors among patients with asymptomatic lung cancer, suggesting that early screening may be useful in detecting cancers that are still curable, according to a new article in the February 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Cancers in the earliest stage, which have not yet spread beyond the lungs, are divided by size into stage IA (tumors less than 30 millimeters in diameter) and stage IB (tumors larger than 30 millimeters in diameter), according to background information in the article. The development of computed tomography (CT) scanning has allowed physicians to detect lung tumors at a smaller size, prompting some to call for more subdivisions of stage I cancers. Though tumor size has been linked to cancer prognosis in patients with symptoms, the relationship between tumor size, metastasis (cancer spread) and prognosis in asymptomatic individuals has been unclear, the authors write.

Claudia I. Henschke, M.D., Ph.D., New York Presbyterian Hospital-Weill Cornell Medical Center, New York, and colleagues from the International Early Lung Cancer Action Program screened 28,689 men and women for lung cancer at 38 institutions worldwide between 1993 and 2004. Four hundred sixty-four patients were diagnosed with lung cancer as the result of the screening. The researchers classified the participants' lung cancers based on their type-small cell or non-small cell-as well as the size (diameter) of their tumors at diagnosis and whether or not they had metastasized. They also recorded the consistency of the tumors as solid, nonsolid or part-solid.

For the 436 patients with non-small cell cancers, which are less aggressive than small-cell cancers, the likelihood of metastasis increased along with tumor size. When the researchers analyzed the tumors by consistency, they found the association strongest for solid tumors, weaker for part-solid tumors and not apparent for nonsolid tumors. For the few (28) cases of small cell cancer, the relationship appeared strong for those tumors as well. The percentages of nonmetastasized cancer of all types were much higher than those reported in previous studies.

"The pattern confirmed herein suggests the usefulness of finding latent cancers at small sizes," the authors conclude. "Most lung cancers without evidence of lymph node metastases are curable, with the curability rate being higher at smaller sizes. This suggests that tumor diameter also serves as a prognostic indicator for curability, perhaps even for micrometastases not detectable by our current techniques."

Publication: The article appears in the February 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
On the web: http://jama.ama-assn.org/ 

Advertise in this space for $10 per month. Contact us today.

Related Lung News
Tamoxifen reduces mortality rate in lung cancer
Lung Cancer risk greater in tuberculosis patients
Genes to identify patients who would benefit from chemotherapy
First-line treatment with erlotinib improved progression-free survival in advanced lung cancer
Genetic variation-Lung cancer drugs work better in the Japanese than in the Americans
Ireland Cancer Center researchers advance lung cancer treatment
Lung cancer screening regimen provides opportunity for cure
MEK inhibitors may be beneficial for lung cancer containing mutations in the BRaf gene
Potential solution to cetuximab-resistance in lung cancers
Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis

Subscribe to Lung Newsletter

Enter your email address:

 Additional information about the news article
(Arch Intern Med. 2006; 166: 321-325)
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)